Severe bone marrow suppression and hepatic dysfunction caused by piperacillin/tazobactam

By He Zhong-Fang   Wu Xin-An   Wang Yan-Ping  

Scandinavian Journal of Infectious Diseases, Vol. 45, Iss. 11, 2013-11 ,pp. : 885-887

Informa Healthcare

Access to resources Recommend Favorite

The use of piperacillin/tazobactam (in association with amikacin) in neonatal sepsis: Efficacy and safety data

By Flidel-Rimon Orna   Friedman Smadar   Leibovitz Eugene   Shinwell Eric  

Scandinavian Journal of Infectious Diseases, Vol. 38, Iss. 1, 2006-01 ,pp. : 36-42

Informa Healthcare

Access to resources Recommend Favorite

Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 8, 2015-08 ,pp. : e136-e139

John Wiley & Sons Inc

Access to resources Recommend Favorite

Suspected piperacillin‐tazobactam induced nephrotoxicity in the pediatric oncology population

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 61, Iss. 2, 2014-02 ,pp. : 366-368

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin–tazobactam

By  

PEDIATRICS INTERNATIONAL, Vol. 60, Iss. 2, 2018-02 ,pp. : 136-141

John Wiley & Sons Inc

Access to resources Recommend Favorite